Navigation Links
Jazz Pharmaceuticals Announces Public Offering of Common Stock
Date:5/10/2010

PALO ALTO, Calif., May 10 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.  All of the shares in the offering are to be sold by Jazz Pharmaceuticals. Barclays Capital Inc. is the sole book-running manager of the offering. Jazz Pharmaceuticals intends to use all of the net proceeds from the offering to repay a portion of its outstanding senior secured notes.  

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted.  Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from: Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and related prospectus supplements, and the other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering.  You may access these documents when available for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the completion of the public offering. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to completion of the public offering. There can be no assurance that Jazz Pharmaceuticals will be able to complete the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the heading "Risk Factors" in Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed with the Securities and Exchange Commission (SEC) on May 6, 2010, and in the preliminary prospectus supplement related to the public offering to be filed with the SEC on May 10, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province
2. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
4. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
5. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
6. DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
7. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
8. ADVENTRX Pharmaceuticals Announces Closing of Financing
9. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
10. Trading Halted Today in Questcor Pharmaceuticals Common Stock
11. HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):